#BlueBalloonChallenge

* Refers to SmartGuard^™ Auto Mode. Some user interaction required.

Blue Balloon Challenge Terms and Conditions for the United States of America

Definitions

Blue Balloon Challenge (BBC) refers to balancing a blue balloon in the air whilst doing a daily activity and subsequently posting this act on social media and tagging Medtronic Diabetes.

Challenge Period means the period commencing 12:00 a.m. PT October 30, 2024 and continuing until 12:00 a.m. PT November 30, 2024.

Donation means the donation to Breakthrough T1D set out in clause ‎4 of these Terms.

Entrant means a person is participating in the BBC in accordance with these Terms.

Entry Material means an Entrant’s BBC including the response and any photos, images, or videos.

Social Media Channels means Facebook, Instagram, and or LinkedIn.

1. There are the terms and conditions of entry into the 2024 Medtronic Diabetes BlueBalloonChallenge and information on how to enter the BBC which form part of these Terms (these Terms). Participation by Entrants in the BBC is deemed acceptance of these Terms. By participating in the BBC, the Entrant acknowledges that they have read, understood and agree to be bound by and abide by these Terms.
2. Medtronic Diabetes may (subject to applicable laws) vary the terms of, or terminate, the BBC at any time prior to, or during, the Challenge Period at its absolute discretion without liability to any Entrant or other person.
3. The Social Media Channels are not sponsoring the BBC and respectively have no control over the BBC or the Donation, however the Entrant agrees to be bound by any applicable terms and conditions of the Social Media Channels by entering into the BBC.



Donation Acknowledgement

4. every BBC performed and publicly shared on Social Media Channels with both the hashtag #blueballoonchallenge and tagging @MedtronicDiabetes during the Challenge Period, Medtronic Diabetes will donate to Breakthrough T1D. Medtronic Diabetes will donate up to USD $30,000.00 to Breakthrough T1D.



Conditions of Entry

5. An Entrant’s entry must not be unlawful or capable of violating any law or giving rise to a civil action; obscene; defamatory or libellous; threatening or harassing; pornographic or contain nudity; hateful; offensive against a person or group of persons on the grounds of age, color, gender, national or ethnic origin, disability, race, religion or sexual preference; incite or be capable of encouraging conduct that would be considered a criminal offence; or in violation of the social media guidelines, rules or terms of service of the Social Media Channels used to enter the BBC.
6. Medtronic Diabetes reserves the right to disqualify any Entry Material counted towards the Donation where it reasonably suspects that such entries are prohibited by these Terms, any relevant law, or are otherwise deemed inappropriate. This is at Medtronic Diabetes’ absolute discretion. All participants acknowledge that Medtronic Diabetes reserves the right to delete and block any Entrant who submits abusive, inflammatory, offensive or other materials deemed inappropriate by the Medtronic Diabetes.
7. Entrants retain all ownership in their Entry Material however, by submitting their Entry Material, Entrants hereby grant Medtronic Diabetes an irrevocable, non-exclusive, worldwide, royalty-free, sub-licensable and transferable license to use, reproduce, distribute, prepare derivative works of and display the Entry Material for the purposes of conducting and promoting the BBC, advertising and marketing Medtronic Diabetes or the BBC on all media now known or later devised, in perpetuity. For the avoidance of doubt, Medtronic Diabetes is not required to seek the Entrant’s prior approval before using the Entry Materials.
8. Each Entrant warrants that they have the full power and capacity to grant the rights, warranties and consents set out in these Terms;
   1. Entry Material is not, and its use by Medtronic Diabetes (or the Entrant) will not be, in breach of any third party intellectual property rights;
   2. will fully indemnify Medtronic Diabetes against any loss or damage suffered by Medtronic Diabetes:
      1. in the event that any of the warranties given by the Entrant are false;
      2. as a result of any breach of these Terms by the Entrant; and
   3. they have consent from each person appearing in the Entry Material (or if a person appearing in the Entry Material is under the age of 18 years, from that person’s parent or guardian).
9. To the extent permitted by law, Medtronic Diabetes shall not be liable for any loss or damage whatsoever (including but not limited to direct or consequential loss) or for any personal injury suffered or sustained, including as a result of the Medtronic Diabetes’ negligence, in connection with the BBC undertaken by any Entrant.
10. Medtronic Diabetes will collect, use and disclose personal information of Entrants in accordance with Medtronic Diabetes’ Privacy Policy for the purpose of the BBC. A request to access, update or correct any personal information should be directed to Medtronic Diabetes at their address set out above. A copy of Medtronic Diabetes’ Privacy Statement is available online at https://www.medtronicdiabetes.com/privacy-policy
11. These conditions are governed by the laws of California.

Important safety information: MiniMed^™ 780G system with SmartGuard^™ technology with Guardian^™ 4 sensor
The MiniMed^™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 780G system includes SmartGuard^™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 780G system consists of the following devices: MiniMed^™ 780G insulin pump, the Guardian^™ 4 transmitter, the Guardian^™ 4 sensor, One-press serter, the Accu-Chek^™ Guide Link blood glucose meter, and the Accu-Chek^™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian^™ 4 sensor is intended for use with the MiniMed^™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian^™ 4 sensor is indicated for up to seven days of continuous use.

The Guardian^™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed^™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ 4 sensor. The Guardian^™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian^™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard^™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard^™ feature.

WARNING: Do not use the MiniMed^™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard^™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed^™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Important Safety Information: Guardian^™ Connect CGM System
The Guardian^™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.

The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.

Important Safety Information: InPen^™
The InPen^™ is a home- use reusable pen injector for single- patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self- injection of a desired dose of insulin and for calculating an insulin dose or carbohydrate intake based on user entered data. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient- specific criteria and targets. The InPen^™ requires a prescription. For additional product and safety information, please consult the Instructions for Use and bit.ly/InPenRisks.